Pozen (POZN +5.3%) gives an update on its Type A meeting with the FDA regarding its drug...

|By:, SA News Editor

Pozen (POZN +5.3%) gives an update on its Type A meeting with the FDA regarding its drug candidate PA32540. Regulators says no additional bioeqivalence studies are needed for the drug, which is intended to reduce the risk of aspirin-induced gastric ulcers in patients as well as preventing cardio- and cerebro-vascular events.